AMGN/Denosumab @ASCO: several post-hoc subset and meta-analyses from the three completed studies in metastatic cancer: http://finance.yahoo.com/news/Amgen-Highlights-Key-Clinical-prnews-2950876243.html?x=0&.v=1 Please see #msg-50215668 for background.